Friday, 20 July 2012

Anthisan Bite & Sting Cream





1. Name Of The Medicinal Product



Anthisan Bite and Sting 2% w/w Cream


2. Qualitative And Quantitative Composition



Mepyramine Maleate 2% w/w














Also contains:




 




Castor oil




23,60% w/w




Ceto-stearyl alcohol




13,80% w/w




Propylene glycol 600 monostearate




4,90% w/w




Methyl hydroxybenzoate




0,20% w/w



For a full list of excipients, see section 6.1



3. Pharmaceutical Form



A smooth off-white cream



4. Clinical Particulars



4.1 Therapeutic Indications



Symptomatic relief of skin irritation caused by insect stings, insect bites and nettle stings.



Route of Administration: Topical



4.2 Posology And Method Of Administration



Adults, elderly and children over 2 years of age and older. Anthisan Bite and Sting Cream should be applied directly to the affected parts two or three times a day for up to three days. Early application is essential to obtain the optimum response.



4.3 Contraindications



Anthisan Bite and Sting Cream should not be used in eczematous conditions or on extensively broken skin surfaces, or if the skin is cut or grazed. Do not use on large areas of skin or on areas of sunburnt skin.



Hypersensitivity to the active substance or to any of the excipients.



4.4 Special Warnings And Precautions For Use



Repeated application of Anthisan Bite and Sting Cream to the same area for longer than three days is not recommended and treatment should be discontinued immediately if skin sensitisation occurs.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No significant interactions described.



4.6 Pregnancy And Lactation



There is no evidence of the safety of mepyramine maleate in human pregnancy, but it has been widely used for many years without apparent ill consequence. Absorption of a significant amount after topical application is unlikely in the prescribed method of use, nevertheless, Anthisan Bite and Sting Cream should not be used during pregnancy or lactation, unless considered essential.



4.7 Effects On Ability To Drive And Use Machines



Anthisan Bite and Sting Cream has minor or moderate influence on the ability to drive and use machines.



May theoretically be extensively absorbed through the skin when applied over large areas and cause somnolence and mild disorientation.



4.8 Undesirable Effects



Skin sensitisation has been reported on rare occasions.



4.9 Overdose



A 20g tube of Anthisan Bite and Sting Cream contains 400mg mepyramine maleate. If accidentally ingested this dose would constitute a dangerous overdose in young children.



The chief symptoms of overdosage is unconsciousness and there may be convulsions in the intervening periods. The stomach should be washed out. Stimuli liable to provoke convulsions should be avoided, but if this complication should occur, parenteral Diazepam should be given, sedatives which are liable to increase respiratory depression should be avoided. Other measures such as artificial respiration and oxygen may also be required and an antibiotic can be given as a prophylactic against pneumonia.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Mepyramine maleate is an antihistamine with anti-pruritic and local analgesic actions.



5.2 Pharmacokinetic Properties



No pharmacokinetic data available by any route of administration.



5.3 Preclinical Safety Data



There are no findings of relevance to the prescriber, additional to those already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Ceto-stearyl alcohol



Polyethylene glycol 600 monostearate



Castor oil



Methyl hydroxybenzoate



Foin coupe (fragrance)



Silicone antifoam



Purified water



6.2 Incompatibilities



Not applicable



6.3 Shelf Life



3 years



6.4 Special Precautions For Storage



Store below 30°C



6.5 Nature And Contents Of Container



Collapsible aluminium tube with extended nozzle and polyethylene screw cap containing 20g cream.



6.6 Special Precautions For Disposal And Other Handling



No special requirements



7. Marketing Authorisation Holder



Sanofi-aventis



One Onslow Street



Guildford



Surrey, GU1 4YS, UK



8. Marketing Authorisation Number(S)



PL 04425/0275



9. Date Of First Authorisation/Renewal Of The Authorisation



September 2005



10. Date Of Revision Of The Text



18 November 2010



LEGAL CATEGORY


GSL




No comments:

Post a Comment